First-trimester hyperglycosylated human chorionic gonadotropin and development of hypertension

2013 ◽  
Vol 33 (11) ◽  
pp. 1075-1079 ◽  
Author(s):  
M. C. Brennan ◽  
M. D. Wolfe ◽  
C. M. Murray-Krezan ◽  
L. A. Cole ◽  
W. F. Rayburn
Keyword(s):  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
First Trimester ◽  
Hyperglycosylated Human Chorionic Gonadotropin

Hyperglycosylated chorionic gonadotropin – prognostic criteria development of complications of pregnancy

2017 ◽  
pp. 82-85
Author(s):  
N.V. Pehnyo ◽  
Keyword(s):  
Pregnant Women ◽  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Prognostic Significance ◽  
Neonatal Morbidity ◽  
First Trimester ◽  
Trophoblast Invasion ◽  
Placental Dysfunction ◽  
Hyperglycosylated Human Chorionic Gonadotropin ◽  
First Trimester Of Pregnancy

The objective: to assess the prognostic significance of the level of serum hyperglycosylated human chorionic gonadotropin (gHCG) reative to the development of pregnancy complications that lead to impaired fetal conditions. Materials and methods. 382 pregnant women were examined who were on the register, were hospitalized in case of complications of pregnancy and gave birth to KCMH №2 (Kiev). All pregnant women were evaluated serum gCGG in the period of 8-10 weeks gestation, evaluated the course and result of pregnancy. Results. Reduction in the level of gHCG is a marker of insufficient trophoblast invasion, which is likely to lead to the formation of placental dysfunction and the development of a variety of obstetric pathology complicating the course of pregnancy and a risk factor for antenatal loss and neonatal morbidity. The conclusion. Determination of the level of hyperglycosylated human chorionic gonadotropin in the first trimester of pregnancy will make it possible to identify pregnant women at risk for the formation of placental dysfunction and propose a set of monitoring activities aimed at early detection of violations of pregnancy and their timely removal. This helps prevent the formation of severe pathological conditions during pregnancy in both the mother and the fetus, which corresponds to the current trends in the development of medical care, namely: prediction, prevention and individual approach. Key words: hyperglycosylated chorionic gonadotrophin, complications of pregnancy, disturbed fetal condition.

scholarly journals Invasive Trophoblast Antigen (Hyperglycosylated Human Chorionic Gonadotropin) as a First-Trimester Serum Marker for Down Syndrome

2005 ◽  
Vol 51 (7) ◽  
pp. 1276-1279 ◽  
Author(s):  
Martin JN Weinans ◽  
Ulrich Sancken ◽  
Raj Pandian ◽  
Jody MW van de Ouweland ◽  
Henk WA de Bruijn ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
First Trimester ◽  
Serum Marker ◽  
Hyperglycosylated Human Chorionic Gonadotropin

Four Years' Experience With an Interlaboratory Comparison Program Involving First-Trimester Markers of Down Syndrome

2010 ◽  
Vol 134 (11) ◽  
pp. 1685-1691
Author(s):  
Glenn E. Palomaki ◽  
George J. Knight ◽  
Geralyn Lambert-Messerlian ◽  
Jacob A. Canick ◽  
James E. Haddow
Keyword(s):  
Down Syndrome ◽  
Chorionic Gonadotropin ◽  
Plasma Protein ◽  
Human Chorionic Gonadotropin ◽  
Interlaboratory Comparison ◽  
Protein A ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Second Trimester ◽  
Coefficients Of Variation

Abstract Context.—We initiated a voluntary, self-funded interlaboratory comparison program in the fall of 2005 because no proficiency testing program was available to laboratories in North America offering first-trimester, combined serum and ultrasound, Down syndrome screening. Objectives.—To evaluate the first 4 years of the interlaboratory comparison program against stated goals, to identify areas of concern, and to create new initiatives as indicated. Design.—Five serum samples are distributed 3 times a year to be tested for pregnancy-associated plasma protein A, human chorionic gonadotropin or its β subunit, and dimeric inhibin-A; participants convert these results into multiples of the median. Patient histories include nuchal translucency information that enables the calculation of the risk of Down syndrome. Also included are educational components linked to interlaboratory comparison program results. Assessment of integrated (first- and second-trimester markers) risks is accomplished by having participants combine interlaboratory comparison program results with their results from a second-trimester proficiency testing program administered by the College of American Pathologists. Results.—The precision profile for pregnancy-associated plasma protein A shows decreasing coefficients of variation with increasing pregnancy-associated plasma protein A concentrations and multiples of the median (25% to 11% and 30% to 15%, respectively). In contrast, coefficients of variation are a relatively constant 12% throughout the entire range of human chorionic gonadotropin results. On a logarithmic scale, the median coefficient of variation of the risk of Down syndrome is 9%. Conclusions.—Participants in the interlaboratory comparison program reliably measure analytes, compute multiples of the median, and calculate consistent Down syndrome risks. Assays for the measurement of pregnancy-associated plasma protein A are not standardized and are less precise than those for human chorionic gonadotropin. Participants calculate reliable median equations given sonographer-specific sets of paired crown-rump length and nuchal translucency measurements.

Sign in / Sign up

Export Citation Format

Share Document